Skip to main content
. Author manuscript; available in PMC: 2019 Aug 1.
Published in final edited form as: Exp Clin Psychopharmacol. 2018 Jun 25;26(4):410–420. doi: 10.1037/pha0000196

Figure 3.

Figure 3

Individual subject sleep parameters on baseline (B) and in the nights after afternoon (16h) treatments with vehicle (Veh) or (A, sleep efficiency; B, sleep latency; C, wake time after sleep onset – WASO) racemic MDMA (0.3, 1.0 and 1.7 mg/kg, i.m.) or (D, sleep efficiency; E, sleep latency; F, WASO) R(−) MDMA (0.3, 1.0 and 1.7 mg/kg, i.m.) (N = 6).